Vaccine for Diabetes—Where Do We Stand?

4Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.

Cite

CITATION STYLE

APA

Chellappan, D. K., Bhandare, R. R., Shaik, A. B., Prasad, K., Suhaimi, N. A. A., Yap, W. S., … Dua, K. (2022, August 1). Vaccine for Diabetes—Where Do We Stand? International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms23169470

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free